Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.
about
Pathogenesis of ANCA-associated vasculitisConditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitidesDermatological and immunological conditions due to nerve lesionsIgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).Diagnosis and treatment of cerebral vasculitis.Pathogenesis of ANCA-associated vasculitis.New features of disease after diagnosis in 6 forms of systemic vasculitisCentral nervous system vasculitis: still more questions than answers.The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patientsEosinophilic pneumonias.Update on diffuse alveolar hemorrhage and pulmonary vasculitis.Hypereosinophilic syndrome induced cystitis mimicking bladder tumorEosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview.Churg-strauss syndrome: an update.Elderly cases of Churg-Strauss syndrome: case report and review of Japanese cases.ANCA-associated vasculitis: report from Korea.Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art.Clinical and laboratory characteristics of 19 patients with Churg-Strauss syndrome from a single South Australian centre.Pulmonary vasculature and critical asthma syndromes: a comprehensive review.Eosinophilic granulomatosis with polyangiitis: an overview.Coronary artery vasculitis: assessment with cardiac multi-detector computed tomography.Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis.Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.ANCA-Associated Vasculitis Pathogenesis: A Commentary.Diagnostic and therapeutic management of Churg-Strauss syndrome.Suppressive effects of ketotifen on Th1- and Th2-related chemokines of monocytes.Churg-strauss syndrome in the pediatric age group.Factors that predict in-hospital mortality in eosinophilic granulomatosis with polyangiitis.Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).An abdominal presentation of churg-strauss syndrome.High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis.Churg-Strauss syndrome associated with montelukast therapy.Effect of delayed diagnosis on disease course and management of Churg-Strauss syndrome: a retrospective study.Churg-Strauss syndrome: retrospective study in Burgundian population in France in past 10 years.Elevated troponins and the Churg-Strauss syndrome: a case report.Getting rid of MPO-ANCA: a matter of disease subtype.
P2860
Q28390438-76A23890-F80E-4A70-A4F7-35156ED6A383Q28393792-4E2F5130-AF97-4311-9259-BE41281D29CCQ30447509-1E6CD147-FEE9-4E05-AD6E-EB62CA483EEBQ33912809-B9EA58BE-4BEB-40CD-BFC5-B5617C101598Q34156332-DF88DBE4-FF69-4320-95E2-762EA7ECFF90Q34296337-254B818F-4DDE-4C0E-974D-AB437A234518Q34938237-F2CCE189-8585-4AE8-AD6B-75A7CFC1C3D6Q35151866-9792C478-2D05-4265-AE0D-D033776893C8Q35166699-08E0EC23-2537-40B4-AC75-A1C70B114966Q35557092-5C3D0014-5020-484D-ADC0-58004A1E0AC4Q35747186-2FB8F602-9B95-4E5B-B3D8-F1DE9D5E46B4Q36086682-E72BD584-9109-4708-8809-152948C2BDA0Q36149065-44BE18D6-6A21-4C5C-894C-B22F0474A160Q36354929-6EA07503-E9BF-4ED0-A3A5-6474750D8478Q36950093-CD42454C-5E89-4C8C-AFEE-D9B890994751Q37615723-D3C6441A-15AF-41A1-893A-FCC445A1B972Q37921646-54626A56-71C8-4386-B1F6-48CCEE963172Q37963548-937619E5-F805-4518-A531-994CDCB7C0C4Q38071922-6A5324B9-396F-45FA-9025-EEC25EC4EFD2Q38075024-337B92A8-120C-4543-9683-2D6E1E2086D6Q38101077-A970813A-E247-4E8A-8EB2-4996BFE1DBA4Q38206113-70145C49-AC92-4C6E-B25C-9D0251EC093DQ38269017-70B0F0DE-067C-44EC-A67D-0C0F30A41FE6Q38405469-D8C62159-4A70-48F5-9103-0AD0BD598E4AQ38719006-0BA2A4D5-8BC7-43BD-882A-FFF448ABDB26Q38837317-2DC01A4D-D190-4EB9-B225-31AD1B0A9A47Q39088103-3A841EA9-AFE8-45F3-BB02-C584DABBDE80Q39210329-7DA91E3E-D354-40AC-814F-46F786B716A0Q39872550-57FFE36F-FD34-4D30-BB1E-6399773A84F1Q40109882-66489844-1F0C-4656-85AC-CAF1B84B4039Q40617823-E35A49BD-C3F2-4976-B989-0EDF70F82CE5Q41373236-297EBFDF-8029-417D-AD40-2CF5DAA306E2Q41444787-AFBEFF7E-C2A0-4B74-AB39-A2D1A242E350Q41889306-4694C5EB-A632-4DBC-9278-1A5F45C58BEFQ42601725-27B00C03-B721-41EC-8B74-0EEBD2868BB5Q43297955-CC31C499-0502-4757-8686-A97A88E7260CQ43776735-A7073473-1FDC-4E32-8780-2AE2519BA2EBQ45063633-4ABA8DBA-D8C5-4B5E-8525-0ED2E4FC0E4CQ46054727-16C48756-08C9-4A1C-9085-E44F00671771Q46876804-A67857A3-BD54-4E8D-934B-945B6E0F74A5
P2860
Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Churg-Strauss syndrome: clinic ...... kotriene receptor antagonists.
@en
Churg-Strauss syndrome: clinic ...... kotriene receptor antagonists.
@nl
type
label
Churg-Strauss syndrome: clinic ...... kotriene receptor antagonists.
@en
Churg-Strauss syndrome: clinic ...... kotriene receptor antagonists.
@nl
prefLabel
Churg-Strauss syndrome: clinic ...... kotriene receptor antagonists.
@en
Churg-Strauss syndrome: clinic ...... kotriene receptor antagonists.
@nl
P1476
Churg-Strauss syndrome: clinic ...... kotriene receptor antagonists.
@en
P2093
Karina A Keogh
Ulrich Specks
P304
P356
10.1016/S0002-9343(03)00359-0
P407
P577
2003-09-01T00:00:00Z